Cost-effectiveness of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis in Belarus, Georgia, Kazakhstan and the Republic of Moldova

IntroductionPrior to 2020, treatment options for multidrug-resistant tuberculosis (MDR-TB) were limited and typically involved long treatment durations and high financial burdens. In the eastern European and central Asian (EECA) region, traditional inpatient tuberculosis (TB) care models, alongside...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	BMJ global health Ročník 10; číslo 11; s. e018099
Hlavní autori:	Allel, Kasim, Palmer, Tom, Abou Jaoude, Gerard Joseph, Korotych, Oleksandr, Yedilbayev, Askar, Vilc, Valentina, Corloteanu, Andrei, Macari, Mariana, Evghenia, Cula, Laticevschi, Dumitru, Shakhimurat-Shaimovich, Ismailov, Anar-Saduakasovna, Rakisheva, Gulzhan-Elbrusovna, Tulepova, Anatolievna-Ryazanet, Daria, Shahrizada-Yergalymovna, Aimbekova, Yatskevich, Natalia, Skrahina, Alena, Zhurkin, Dmitry, Avaliani, Zaza, Kiria, Nana, Lomtadze, Nino, Kiria, Nino, Avaliani, Teona, Khonelidze, Irma, Danelia, Maka, Maxim, Corina, Haghparast-Bidgoli, Hassan, Skordis, Jolene
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England BMJ Publishing Group Ltd 08.11.2025 BMJ Publishing Group
Predmet:	Administration, Oral Adult Antitubercular Agents - administration & dosage Antitubercular Agents - economics Antitubercular Agents - therapeutic use Cost-Benefit Analysis Female Georgia (Republic) Health economics Humans Kazakhstan Male Middle Aged Moldova Original research Quality-Adjusted Life Years Republic of Belarus Rifampin - administration & dosage Rifampin - therapeutic use Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - economics Republic of Belarus Moldova Georgia (Republic) Kazakhstan Health economics Tuberculosis
ISSN:	2059-7908, 2059-7908
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!